title: Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma.
abstract: The prognostic value of the sentinel lymph node in Merkel cell carcinoma (MCC) has been examined previously in heterogeneous retrospective studies. The current retrospective study included a homogeneous population of patients with a localized MCC, all staged with sentinel lymph node biopsy. Factors associated with 3-year progression-free survival were analysed using logistic regression. The sentinel lymph node was positive in 32% of patients. The recurrence rate was 26.9%. In first analyses (n = 108), gender (p = 0.0115) and the presence of immunosuppression (p = 0.0494) were the only significant independent factors. In further analyses (n = 80), excluding patients treated with regional radiotherapy, sentinel lymph node status was the only significant prognostic factor (p = 0.0281). Immunosuppression and positive sentinel lymph node are associated with a worse prognosis in patients with MCC. Nodal irradiation impacts on the prognostic value of the sentinel lymph node status.
authors.affiliation: Department of Dermatology, Hôpital Saint André, CHU Bordeaux, Bordeaux, France. thomas.jouary@ch-pau.fr.
authors.forename: Thomas
authors.initials: T
authors.lastname: Jouary
authors.forename: Emeline
authors.initials: E
authors.lastname: Kubica
authors.forename: Stéphane
authors.initials: S
authors.lastname: Dalle
authors.forename: Cecile
authors.initials: C
authors.lastname: Pages
authors.forename: Anne-Benedicte
authors.initials: AB
authors.lastname: Duval-Modeste
authors.forename: Bernard
authors.initials: B
authors.lastname: Guillot
authors.forename: Sandrine
authors.initials: S
authors.lastname: Mansard
authors.forename: Philippe
authors.initials: P
authors.lastname: Saiag
authors.forename: François
authors.initials: F
authors.lastname: Aubin
authors.forename: Christophe
authors.initials: C
authors.lastname: Bedane
authors.forename: Sophie
authors.initials: S
authors.lastname: Dalac
authors.forename: Anne
authors.initials: A
authors.lastname: Dompmartin
authors.forename: Florence
authors.initials: F
authors.lastname: Granel-Brocard
authors.forename: Catherine
authors.initials: C
authors.lastname: Lok
authors.forename: Pierre-Emmanuel
authors.initials: PE
authors.lastname: Stoebner
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Lacour
authors.forename: Marie-Therese
authors.initials: MT
authors.lastname: Leccia
authors.forename: Abou
authors.initials: A
authors.lastname: Diallo
authors.forename: Khaled
authors.initials: K
authors.lastname: Ezzedine
authors.forename: Christina
authors.initials: C
authors.lastname: Mateus
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015266:Carcinoma, Merkel Cell / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D005602:France; D006801:Humans; D016867:Immunocompromised Host; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D021701:Sentinel Lymph Node Biopsy; D012737:Sex Factors; D012878:Skin Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult